Chemoreduction in the initial management of intraocular retinoblastoma
Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma
A phase I/II study of direct intra-arterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma
- initial results.
Ultrasonic findings in intraocular retinoblastoma
and correlation with histopathologic diagnosis.
Treatment of intraocular retinoblastoma
with vincristine and carboplatin.
As retinoblastomas form within the retina, we hypothesized that sd-rxRNAs might also regulate gene expression in intraocular retinoblastoma
Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma
There are few studies that have evaluated HRFs in eyes enucleated for advanced intraocular retinoblastoma
from developing countries, and most of them have reported higher incidences compared with studies reported in the Western literature.
Pilot studies of chemotherapy for intraocular retinoblastoma
have been reported from several groups using different combinations, dosages, schedules and duration of carboplatin, etoposide or teniposide, with or without vincristine, and with or without cyclosporine to counteract multidrug resistance.
Only patients with unilateral advanced intraocular retinoblastoma
that have received no previous treatment will be eligible for clinical trial enrollment.
Combined chemotherapy and local treatment in the management of intraocular retinoblastoma
The protocol of chemotherapy is the same as that used for chemoreduction of intraocular retinoblastoma
(12); the protocol is changed to 12 cycles of high-dose chemotherapy for patients with involvement of the optic nerve to the transection line and scleral and extrascleral extension.